Clinical and Immunohisochemical Evaluation of Chemopreventive Effect of Thymoquinone on Oral Potentially Malignant Lesions.
Status:
Completed
Trial end date:
2020-03-12
Target enrollment:
Participant gender:
Summary
The present randomized, controlled, parallel-grouped trial includes 48 patients (aged 18 to
75 years) suffering from oral potential premalignant lesions. Patients will be randomly
assigned into 3 equal groups: Group A: Nigella Sativa buccal tablets group 10mg Group B:
Nigella Sativa buccal tablets 5 mg Group C:Control group (placebo)